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Disturbances in the potassium homeostasis are common among patients with heart
failure (HF) and negatively affect clinical outcome. Patients with HF have a higher
prevalence of common risk factors related to hyperkalaemia, including diabetes mel-
litus, hypertension, and chronic kidney disease. Furthermore, the use of renin–
angiotensin–aldosterone system (RAAS) inhibitors, is an important risk factor for de-
veloping hyperkalaemia. The association between hyperkalaemia and mortality is
not unequivocal, depends on the study type (trial vs. real-world setting) and is often
confounded. More importantly, hyperkalaemia is an important cause of discontinua-
tion or failure to uptitrate to guideline recommended dosages of RAAS inhibitors,
which in turn may negatively impact clinical outcomes. The goal of this review is to
discuss the epidemiology, aetiology, and clinical consequences of potassium distur-
bances in HF.
Introduction
Potassium levels are often routinely measured in patients
with heart failure (HF) and HF guidelines recommend fre-
quent measurement of potassium during hospitalization for
HF.1 In the general population, disturbances in potassium
homeostasis are associated with (insulin dependent) diabe-
tes, chronic kidney disease, hypertension and use of renin–
angiotensin–aldosterone system (RAAS) inhibitors, as well
as diuretics.2–4 Hyperkalaemia is associated with worse out-
comes in patients with HF as well as with discontinuation or
a reduction of RAAS inhibitors, which may impact sur-
vival.5–8 Therefore, hyperkalaemia warrants specific atten-
tion. This is even more relevant due to the emergence of
new treatment possibilities including novel potassium bind-
ing agents.9 This review summarizes the aetiology, epide-
miology, and clinical consequences of hyperkalaemia in HF.
Clinical causes and aetiology of
hyperkalaemia
Hyperkalaemia is an often observed and potentially dan-
gerous event in patients with HF. Yet, in patients with HF,
volume overload and activation of the RAAS will lead to po-
tassium excretion and sodium reabsorption in the proximal
tubule of the kidney, which suggests that patients with HF
have a tendency for lower potassium levels. Then why is
hyperkalaemia an often-observed event in patients with
HF? Hyperkalaemia is caused by a complex interplay of
both environmental as well as physiological factors.
Predictors of hyperkalaemia in the Candesartan in Heart
Failure-Assessment of Reduction in Mortality and Morbidity
(CHARM) program included age75 years, male gender, di-
abetes, creatinine 2.0mg/dL, and background use of
angiotensin-converting enzyme (ACE) inhibitors or spirono-
lactone. Furthermore, candesartan increased the risk of
hyperkalaemia from 1.8% in placebo to 5.3%, however, in
this post hoc analysis no strict threshold for hyperkalaemia
was defined as the definition of hyperkalaemia as an
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adverse event was determined by the treating physician.7
These findings were confirmed in other randomized con-
trolled trials including the Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure
(EMPHASIS-HF) trial, the Trial of Intensified vs. Standard
Medical Therapy in Elderly Patients with Congestive Heart
Failure (TIME-CHF), in a retrospective analysis of the
Studies of Left Ventricular Dysfunction (SOLVD) trials and in
a more recent example of a real-world population from the
BIOSTAT-CHF study, (Figure 1).8,10–12 Particularly in the
BIOSTAT-CHF study, the prevalence of hyperkalaemia
showed a distinct geographical distribution independent of
risk factors for developing hyperkalaemia including age,
sex, usage of RAAS inhibition, and the presence of diabetes
mellitus and hypertension, suggesting possible differences
in potassium monitoring as well as clinical practice across
Europe (Figure 2).10
In physiological conditions, potassium is sequestrated
from the plasma, creating an equilibrium between potas-
sium intake and excretion. Two processes are key, first the
Naþ/Kþ ATPase pump is important for exchanging intracel-
lular Naþ for extracellular Kþ.5,13–15 This process is of par-
ticular importance in stress situations under the influence
from the sympathetic nervous system through beta-2-
receptors as well as insulin, where cellular uptake of potas-
sium is increased following an increased potassium load.16
Following, potassium homeostasis is established mostly by
excretion of potassium via urine. This also explains the key
importance of renal function in potassium homeostasis. In
physiological circumstances, potassium is filtered through
the glomerular capillaries and excreted by the distal col-
lecting duct. This process is highly dependent on adequate
function of the RAAS and renal perfusion as well as sodium
availability to the distal nephron.15 Hence, disturbance of
the RAAS, reduction of renal perfusion and reduction in so-
dium availability are all risk factors for hyperkalaemia.
In the case of HF all these processes are disturbed: the
RAAS is up-regulated, renal perfusion is reduced and so-
dium is often excreted due to usage of diuretics.
Particularly in diabetics, the elderly, and patients on RAAS
inhibition, aldosterone production is reduced.17,18
Additional age dependent reduction in the availability of
nephrons further increases the risk for hyperkalaemia.19 In
addition, beta-blockers are also associated with a de-
creased cellular uptake of potassium by inhibition of the
sympathetic nervous system, which increases the risk for a
hyperkalaemic event.16 The association between hyper-
tension and hyperkalaemia is characterized by pseudohy-
poaldosteronism, renal tubular unresponsiveness to
aldosterone, which leads to hyperkalaemia and metabolic
acidosis.20 However, the association between hypertension
and hyperkalaemia in HF is not unequivocal and previous
reports might have been confounded by renal function and
medication use.
Incidence and prevalence of hyperkalaemia
in heart failure
The overall reported incidence of hyperkalaemia differs
depending on the study setting (trial vs. registry) and
severity (acute vs. chronic) of HF. Among clinical trials in-
volving RAAS inhibitors as a monotherapy, the incidence of
hyperkalaemia ranges from 3% to 7% (Figure 3). In the
Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS), incidence rates of hyperkalaemia were al-
most double (7.1% vs. 4.0%) in the group treated with enal-
april compared with placebo during a mean 188days
follow-up.21 In the SOLVD trials, where patients were also
randomized to either placebo or enalapril, the incidence
rates of hyperkalaemia during a mean follow-up of
2.7 years were 6% in the treatment group and 4.2% in the
placebo group.12,22 When a definition of 6.0mEq/L was
used as a definition of hyperkalaemia, the incidence rate in
the treatment group dropped to 1.1%.12,22 Nevertheless,
the incidence in the SOLVD and CONSENSUS trials are
largely underestimating contemporary rates of hyperkalae-
mia, as both trials were performed in an era where no other
background RAAS inhibition was prescribed.22 In the results
of Candesartan in Heart failure-Assessment of moRtality
and Morbidity (CHARM) alternative trial, where 2258
patients intolerant to ACE inhibitors were randomized to
candesartan or placebo, incidence hyperkalaemia
(>6.0mEq/L) was 3% compared with 1.3% in the placebo
group during a median follow-up of 33.7months. Here,
hyperkalaemia was defined as a potassium level of
>6.0mEq/L.23 When candesartan was added to treatment
with background ACE inhibition in the CHARM-Added trial,
overall incidence rates of hyperkalaemia were 3% in the
treatment arm compared with 1% in the placebo arm dur-
ing a 41months median follow-up time.24 The relatively
lower incidence rates of hyperkalaemia in the treatment
arm of the CHARM-added trial (3% in 41months median
follow-up) compared with the CHARM-alternative trial (3%
in 33.7months median follow-up), can potentially be
explained by differences in the study population. Patients
included in the CHARM-alternative trial had a higher preva-
lence of background treatment with spironolactone (25% in
CHARM-alternative vs. 17% in CHARM-added), which based
on previous results from a follow-up to the RALES trial is an
important risk factor for developing hyperkalaemia when
additional RAAS inhibition is added.23–25
Figure 1 Factors in patients with heart failure associated with
hyperkalaemia.
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In trials involving aldosterone inhibition, overall inci-
dence rates of hyperkalaemia were on average higher. In
the EMPHASIS-HF study, where 2737 patients were either
randomized to the MRA eplerenone or placebo, incident
hyperkalaemia (>5.5mEq/L) was 8.0% in the treatment
group compared with 3.7% in the placebo group.8,26
However, the incidence rate of hyperkalaemia in this study
is probably underestimated as patients with potassium lev-
els >5.0mEq/L were excluded at study inclusion.26 In the
Eplerenone Post-Acute Myocardial Infarction Heart Failure
Efficacy and Survival Study (EPHESUS), 6632 patients with
acutemyocardial infarction complicated by left ventricular
dysfunction and HF, incidence rates of hyperkalaemia were
15.6% in the patient group treated with eplerenone vs.
11.2% in the placebo group during a 16month mean follow-
up, but again similar to the EMPHASIS-HF trial, patients
with potassium of>5.0mEq/Lwere excluded.27 In contrast
to the EMPHASIS-HF and EPHESUS trials, the Randomized
Aldactone Evaluation Study (RALES) reported rates of
hyperkalaemia (>6.0mEq/L) with 2% in the study group
treated with spironolactone vs. 1.4% in the placebo group
during a follow-up of 24months.28 The overall incident
rates of hyperkalaemia seemed lower in the RALES trial
due to the stricter definition of hyperkalaemia (>6.0mEq/
L) and the lower prevalence of background RAAS inhibition
by ACE inhibitors/angiotensin II receptor blockers (ARB).26–
28 The fact that this considerably influenced incidence
rates of hyperkalaemia is further supported by a follow-up
study, which showed that after the introduction of spirono-
lactone on top of treatment with ACE inhibitors, the rate of
hospitalization for hyperkalaemia rose from 2.4 per 1000
patients in 1994 to 11.0 per 1000 patients in 2001.25
A more recent study is the Prospective Comparison of
ARNI with ACEI to Determine Impact on Global Mortality
and Morbidity in Heart Failure (PARADIGM-HF) study, which
saw 8399 patients randomized to either entresto or enala-
pril in addition to recommended therapy. Incidence rates
were considerably higher in this trial compared with previ-
ous trials involving RAAS inhibition, incidence rates of
hyperkalaemia were similar between patients treated with
entresto (16.1%) and enalapril (17.3). When using a more
stringent definition of >6.0mEq/L, patients treated with
entresto (4.3%) had lower incidence rates (P¼ 0.007) of
hyperkalaemia compared with patients treated with enala-
pril (5.6%).29 The fact that concomitant usage of entresto
on top of background therapy can reduce the risk for inci-
dent hyperkalaemia, particularly in patients treated with
background MRA, is further supported by a recent post hoc
analysis of the PARADIGM-HF trial.30
In trials with HF patients with preserved ejection frac-
tion (HFpEF) incidence rates of hyperkalaemia are arguably
lower (Figure 3).31–33 In the CHARM-preserved trial, where
patients with HFpEF were randomized to candesartan or
placebo, incidence rates of hyperkalaemia (defined as
>6.0mEq/L) were 2% in both groups during a median
follow-up of 36.6months.32 In the Irbesartan in HF patients
Figure 2 Differences in prevalence of hyperkalaemia across Europe (reproduced with permission from de Denus et al.12).
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with a preserved ejection fraction (I-PRESERVE) trial, inci-
dence rates of hyperkalaemia (defined as >6.0mEq/L)
were slightly higher in the treatment group (3%) vs. the pla-
cebo group (2%, P¼ 0.01), however, this did not lead to
more drug discontinuation.33 In the Treatment of Preserved
Cardiac Function Heart Failure with an Aldosterone
Antagonist (TOPCAT) trial, patients from the Americas with
HFpEF treated with spironolactone had higher incidence
rates of hyperkalaemia (18.7%) compared with placebo
(9.1%) during a follow-up of 3.3 years.31,34 Although also
here, similar to the Mineralocorticoid receptor antagonist
(MRA) trials in patients with HF with reduced ejection frac-
tion (HFrEF), patients with HFpEF and a potassium of
5.5mEq/L within the 6months prior or 5.0mEq/L in
2weeks prior to randomization were excluded.31
Among patients with acute HF, hyperkalaemia occurred in
7.8% of patients treated with tolvaptan and 6.6% of patients
treated with placebo in the Efficacy of Vasopressin
Antagonism in Heart Failure Outcome Study With Tolvaptan
(EVEREST) trial.35 In a cross-sectional post hoc analysis from
the Patients Hospitalized with acute heart failure and Volume
Overload to Assess Treatment Effect on Congestion and Renal
FuncTion (PROTECT) trial, hyperkalaemia occurred only in 1%
of overall study participants with no difference between
study drug and placebo.36 However, patients with potassium
<3.0mEq/L at admission were excluded from this study, so
the overall prevalence could be lower in a real-world setting.
Similarly, only 3% of patients in the Coordinating Study
Evaluating Outcomes of Advising and Counseling Failure
(COACH) trial showed potassium levels >5.5mEq/L.36
However, in both these studies only cross-sectional measure-
ments of potassiumwere taken into account.
Clinical consequences of hyperkalaemia
Hyperkalaemia has two important clinical consequences.
The first one is a direct effect on clinical outcomes by caus-
ing possible fatal arrhythmias. The second clinical conse-
quence of hyperkalaemia is discontinuation or down
titration of key HF drugs, which may indirectly affect clini-
cal outcomes.
Whether potassium is an independent risk factor for out-
come or a consequence of other risk factor remains
unclear.5,35–38 A follow-up study after publication of the
RALES trial reported an increase in hyperkalaemia related
mortality.25 In acute HF, post hoc analyses from the
PROTECT, COACH, and EVEREST trials potassium levels at
admission or a change of potassium levels during hospitali-
zation did not show a significant association with post-
discharge survival.35,36 Similarly, hyperkalaemia was not as-
sociated with increases in mortality in both the EPHESUS
and EMPHASIS-HF trials.8,39 The fact that hyperkalaemia
was not associated with increased mortality in many of
Figure 3 Prevalence of hyperkalaemia across heart failure trials (A). Discontinuation of study drug due to hyperkalaemic events across heart failure tri-
als (B). Asterisk (*) denotes a deﬁnition of hyperkalaemia as >6.0mEq/L.
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these trials can potentially be explained by the controlled
settings in which these trials took place. Indeed, potassium
was routinely monitored in these trials and overall tightly
controlled, hence very high potassium levels (>6.0mEq/L)
were relatively rare in these trials. Further proof for this is
provided by two recent real-world studies, which showed a
significant association between hyperkalaemia and an in-
creased mortality.40,41 In the first study, Nu´~nez et al.40
showed that among 2164 patients with a total of 16 116 po-
tassium observation measured at every physician-patient
encounter (including hospital admissions and ambulatory
settings) hyperkalaemia (>5.0mEq/L) was associated with
an increased mortality. Similarly, in a study by Aldahl
et al.41 among 19 549 patients with HF, hyperkalaemia was
associated with increase mortality rates. In a very recent
individual-level data meta-analysis of 27 international
cohorts from the general population, both hypo- and hyper-
kalaemia was associated with more adverse outcomes.42 In
these real-world studies the overall distribution of potas-
sium levels was wider compared with trial, which suggests
an increased mortality risk of hyperkalaemia potentially
occurs at higher potassium levels compared with the con-
ventional>5.0mEq/L or>5.5mEq/L threshold.41
The second and perhaps most important clinical conse-
quence of hyperkalaemia is discontinuation of lifesaving
medication for HF. Indeed, in both the CHARM-alternative
as well as the CHARM added trials, the study drugs were
discontinued in respectively 1.9% and 3.4% of participants,
which were higher rates compared with the placebo
arm.23,24 Also, in the EPHESUS and EMPHASIS studies,
eplerenone was discontinued in 0.7% and 1.1% of
patients.26,27 Perhaps most importantly, the occurrence of
hyperkalaemia did not affect the survival benefit of RAAS
inhibitors.6–8,39 Further proof for this was provided in a
real-world study from the BIOSTAT-CHF study group.10,43 In
this study, potassium levels were measured as part of the
study protocol in 1666 patients with HF and a reduced ejec-
tion fraction. Patients were sub-optimally treated at base-
line. The authors showed that higher levels of baseline
potassium were independently associated with lower upti-
tration rates of RAAS inhibition after 3months of the study.
Furthermore, we showed that there was no significant in-
teraction between potassium or a change in potassium and
the beneficial effects of uptitration to guideline recom-
mended levels of RAAS inhibition.10
Conclusion
Concluding, a combination of a higher prevalence of risk
factors including diabetes mellitus, older age, renal failure,
hypertension, and usage of medication that increases po-
tassium levels, put patients with HF at considerable risk for
hyperkalaemia. Hyperkalaemia is potentially associated
with adverse clinical outcomes andmight lead to reductions
or even discontinuation of RAAS inhibitors. Taken together,
this warrants closer monitoring of potassium levels.
Furthermore, novel potassium binding agents might be use-
ful in patients with HF and may allow for more adequate
uptitration of RAAS inhibitors, which in turn can have an im-
pact on clinical outcomes in these patients.9,44–46
Conflict of interest: P.v.d.M: Consultancy for Vifor Pharma,
AstraZeneca and Novartis. Unrestricted grant from Vifor Pharma
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